PRESS-RELEASE ·Filed Jul 29, 2026

VNDA

Vanda Pharmaceuticals Inc.
BEARISH
Impact 7/10
Horizonweeks Processed2mo ago WireGlobeNewswire
Press release: earnings
Actionable Insight ▼ Bearish

The persistent pattern of EPS misses and negative guidance trajectory suggests continued operational headwinds. Traders should watch for any pipeline updates or cost-cutting measures in the upcoming Q2 2026 earnings call on August 5, 2026, as the current trajectory implies further downside risk.

DirectionBearish
Confidencehigh
Horizonweeks
Latest settled — T+20d ⚠ clustered
VNDA ▲ +5.02% at T+20d
SHORT call ✗ call lost -5.02% · α vs SPY -1.05% · entry $5.18 → $5.44
Next anchor: T+60d in 20d
Latest observation: T+44 -16.62% FF3 residual α
Entry anchored
Jul 29, 03:59 PM ET
via exchange tick
T+1d
-1.54%
call +1.54% · α +2.25%
$5.10
settled 2mo ago
T+5d
-1.25%
call +1.25% · α +4.88%
$5.12
settled 8w ago
T+20d
+5.02%
call -5.02% · α -1.05%
$5.44
settled 5w ago
T+60d
—
call — · α —
—
in 20d

Price Chart

Loading chart...

Executive Summary

Vanda Pharmaceuticals reported Q1 2026 EPS of -$0.82, a 39.6% miss vs consensus of -$0.59, with revenue of $61.9M. The earnings miss is significant and continues a pattern of negative EPS surprises over the past four quarters, indicating ongoing operational challenges. The stock has historically shown high volatility around filings but negative average T+20 returns, suggesting limited sustained upside from this event.

Key Financial Metrics

EPS
$-0.82
est $-0.59 · -39.6%
Revenue
$61.9M
est $61.9M · 0.0%
Rating
strong miss

Key Facts

  • Q1 2026 EPS of -$0.82 missed consensus of -$0.59 by 39.6%
  • Revenue of $61.9M was in line with consensus
  • This is the fourth consecutive quarter of EPS misses (Jun 2025: -35.3%, Sep 2025: -22.6%, Mar 2026: -54.7%)
  • Next quarter Street consensus is -$0.50, suggesting no near-term improvement expected

Financial Impact

EPS miss of -$0.23 per share vs consensus, representing a 39.6% negative surprise

epsrevenue

Risk Factors

  • Continued EPS misses could lead to further analyst downgrades
  • No positive catalysts identified in the filing to reverse the negative trend
  • Historical T+20 returns on VNDA filings have been negative on average

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
80% bullish (10 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302838270
2 reports for VNDA
Performance horizon
Filters
Rows
Reports for VNDA — sortable, filterable
TypeNow
Jul 29, 2026
9w ago
Press Release
BEARISH ★ 7/10
$5.18 $5.44▼ −5.02%▼ −1.05%$4.57 (+11.68%)
May 6, 2026
21w ago
8-K
MIXED ★ 6/10
$6.39 $6.09▼ −4.69%▼ −7.83%$4.57 (−28.40%)
Showing 2 of 2

US Market Status

Market Open — Closes in 48m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jul 29, 2026